nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS1—ulcerative colitis	0.188	0.636	CbGaD
Nepafenac—PTGS2—ulcerative colitis	0.108	0.364	CbGaD
Nepafenac—Magnesium salicylate—Olsalazine—ulcerative colitis	0.103	0.342	CrCrCtD
Nepafenac—Bromfenac—Balsalazide—ulcerative colitis	0.0904	0.3	CrCrCtD
Nepafenac—Fenbufen—Balsalazide—ulcerative colitis	0.0541	0.179	CrCrCtD
Nepafenac—Salsalate—Olsalazine—ulcerative colitis	0.0539	0.179	CrCrCtD
Nepafenac—PTGS2—Olsalazine—ulcerative colitis	0.0531	0.154	CbGbCtD
Nepafenac—PTGS2—Balsalazide—ulcerative colitis	0.0473	0.138	CbGbCtD
Nepafenac—PTGS1—Olsalazine—ulcerative colitis	0.0448	0.13	CbGbCtD
Nepafenac—PTGS1—Balsalazide—ulcerative colitis	0.0399	0.116	CbGbCtD
Nepafenac—PTGS2—Mesalazine—ulcerative colitis	0.0378	0.11	CbGbCtD
Nepafenac—PTGS1—Mesalazine—ulcerative colitis	0.0319	0.0929	CbGbCtD
Nepafenac—PTGS2—Triamcinolone—ulcerative colitis	0.0211	0.0615	CbGbCtD
Nepafenac—PTGS2—Sulfasalazine—ulcerative colitis	0.0211	0.0615	CbGbCtD
Nepafenac—PTGS2—Betamethasone—ulcerative colitis	0.0181	0.0527	CbGbCtD
Nepafenac—PTGS1—Sulfasalazine—ulcerative colitis	0.0178	0.0519	CbGbCtD
Nepafenac—PTGS2—Dexamethasone—ulcerative colitis	0.0105	0.0307	CbGbCtD
Nepafenac—Corneal thinning—Betamethasone—ulcerative colitis	0.00132	0.0286	CcSEcCtD
Nepafenac—Corneal thinning—Dexamethasone—ulcerative colitis	0.00132	0.0286	CcSEcCtD
Nepafenac—Scab—Budesonide—ulcerative colitis	0.00114	0.0246	CcSEcCtD
Nepafenac—Vitreous detachment—Dexamethasone—ulcerative colitis	0.00109	0.0236	CcSEcCtD
Nepafenac—Vitreous detachment—Betamethasone—ulcerative colitis	0.00109	0.0236	CcSEcCtD
Nepafenac—Rheumatoid arthritis—Mesalazine—ulcerative colitis	0.000974	0.0211	CcSEcCtD
Nepafenac—Eye swelling—Mesalazine—ulcerative colitis	0.000902	0.0195	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—CDH3—ulcerative colitis	0.000862	0.107	CbGpPWpGaD
Nepafenac—Corneal oedema—Betamethasone—ulcerative colitis	0.000853	0.0185	CcSEcCtD
Nepafenac—Corneal oedema—Dexamethasone—ulcerative colitis	0.000853	0.0185	CcSEcCtD
Nepafenac—Ulcerative keratitis—Prednisolone—ulcerative colitis	0.000848	0.0183	CcSEcCtD
Nepafenac—Impaired healing—Budesonide—ulcerative colitis	0.000836	0.0181	CcSEcCtD
Nepafenac—Intraocular pressure increased—Budesonide—ulcerative colitis	0.000822	0.0178	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—CDH3—ulcerative colitis	0.000684	0.0846	CbGpPWpGaD
Nepafenac—Sensation of foreign body—Prednisolone—ulcerative colitis	0.000657	0.0142	CcSEcCtD
Nepafenac—Conjunctival oedema—Dexamethasone—ulcerative colitis	0.000644	0.0139	CcSEcCtD
Nepafenac—Conjunctival oedema—Betamethasone—ulcerative colitis	0.000644	0.0139	CcSEcCtD
Nepafenac—Ulcerative keratitis—Prednisone—ulcerative colitis	0.000616	0.0133	CcSEcCtD
Nepafenac—Eye irritation—Nicotine—ulcerative colitis	0.000615	0.0133	CcSEcCtD
Nepafenac—Lacrimation increased—Nicotine—ulcerative colitis	0.00057	0.0123	CcSEcCtD
Nepafenac—Sensation of foreign body—Dexamethasone—ulcerative colitis	0.000548	0.0119	CcSEcCtD
Nepafenac—Sensation of foreign body—Betamethasone—ulcerative colitis	0.000548	0.0119	CcSEcCtD
Nepafenac—Blood pressure increased—Nicotine—ulcerative colitis	0.000525	0.0114	CcSEcCtD
Nepafenac—Impaired healing—Prednisolone—ulcerative colitis	0.000495	0.0107	CcSEcCtD
Nepafenac—Conjunctival hyperaemia—Prednisolone—ulcerative colitis	0.000487	0.0105	CcSEcCtD
Nepafenac—Intraocular pressure increased—Prednisolone—ulcerative colitis	0.000487	0.0105	CcSEcCtD
Nepafenac—Impaired healing—Hydrocortisone—ulcerative colitis	0.000484	0.0105	CcSEcCtD
Nepafenac—Intraocular pressure increased—Hydrocortisone—ulcerative colitis	0.000476	0.0103	CcSEcCtD
Nepafenac—Diclofenac—CXCR1—ulcerative colitis	0.000473	0.147	CrCbGaD
Nepafenac—Impaired healing—Triamcinolone—ulcerative colitis	0.000455	0.00986	CcSEcCtD
Nepafenac—Impaired healing—Methylprednisolone—ulcerative colitis	0.000454	0.00983	CcSEcCtD
Nepafenac—Intraocular pressure increased—Triamcinolone—ulcerative colitis	0.000448	0.00969	CcSEcCtD
Nepafenac—Intraocular pressure increased—Methylprednisolone—ulcerative colitis	0.000447	0.00967	CcSEcCtD
Nepafenac—PTGS2—Fluocinonide—Budesonide—ulcerative colitis	0.000444	0.247	CbGdCrCtD
Nepafenac—Ketoprofen—CXCR1—ulcerative colitis	0.000419	0.13	CrCbGaD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—CHP1—ulcerative colitis	0.000415	0.0513	CbGpPWpGaD
Nepafenac—Impaired healing—Dexamethasone—ulcerative colitis	0.000413	0.00894	CcSEcCtD
Nepafenac—Impaired healing—Betamethasone—ulcerative colitis	0.000413	0.00894	CcSEcCtD
Nepafenac—Conjunctival hyperaemia—Betamethasone—ulcerative colitis	0.000406	0.00879	CcSEcCtD
Nepafenac—Intraocular pressure increased—Betamethasone—ulcerative colitis	0.000406	0.00879	CcSEcCtD
Nepafenac—Intraocular pressure increased—Dexamethasone—ulcerative colitis	0.000406	0.00879	CcSEcCtD
Nepafenac—Conjunctival hyperaemia—Dexamethasone—ulcerative colitis	0.000406	0.00879	CcSEcCtD
Nepafenac—Dermatitis atopic—Mesalazine—ulcerative colitis	0.000397	0.0086	CcSEcCtD
Nepafenac—Arthritis—Nicotine—ulcerative colitis	0.000392	0.00849	CcSEcCtD
Nepafenac—Cataract—Budesonide—ulcerative colitis	0.00038	0.00822	CcSEcCtD
Nepafenac—Endophthalmitis—Dexamethasone—ulcerative colitis	0.000375	0.00812	CcSEcCtD
Nepafenac—Endophthalmitis—Betamethasone—ulcerative colitis	0.000375	0.00812	CcSEcCtD
Nepafenac—Impaired healing—Prednisone—ulcerative colitis	0.00036	0.00779	CcSEcCtD
Nepafenac—Intraocular pressure increased—Prednisone—ulcerative colitis	0.000354	0.00766	CcSEcCtD
Nepafenac—Keratitis—Prednisolone—ulcerative colitis	0.00033	0.00715	CcSEcCtD
Nepafenac—Endophthalmitis—Prednisone—ulcerative colitis	0.000327	0.00707	CcSEcCtD
Nepafenac—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—ulcerative colitis	0.00031	0.0383	CbGpPWpGaD
Nepafenac—Visual acuity reduced—Dexamethasone—ulcerative colitis	0.0003	0.0065	CcSEcCtD
Nepafenac—Visual acuity reduced—Betamethasone—ulcerative colitis	0.0003	0.0065	CcSEcCtD
Nepafenac—Blepharitis—Dexamethasone—ulcerative colitis	0.000291	0.00629	CcSEcCtD
Nepafenac—Blepharitis—Betamethasone—ulcerative colitis	0.000291	0.00629	CcSEcCtD
Nepafenac—Dermatitis atopic—Prednisolone—ulcerative colitis	0.000289	0.00626	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IKZF1—ulcerative colitis	0.000281	0.0348	CbGpPWpGaD
Nepafenac—Sinusitis—Nicotine—ulcerative colitis	0.000276	0.00597	CcSEcCtD
Nepafenac—Keratitis—Dexamethasone—ulcerative colitis	0.000276	0.00596	CcSEcCtD
Nepafenac—Keratitis—Betamethasone—ulcerative colitis	0.000276	0.00596	CcSEcCtD
Nepafenac—Dry eye—Mesalazine—ulcerative colitis	0.000272	0.00588	CcSEcCtD
Nepafenac—Arthritis—Budesonide—ulcerative colitis	0.00027	0.00585	CcSEcCtD
Nepafenac—Dermatitis atopic—Triamcinolone—ulcerative colitis	0.000266	0.00576	CcSEcCtD
Nepafenac—Eye irritation—Prednisolone—ulcerative colitis	0.000251	0.00543	CcSEcCtD
Nepafenac—Immune system disorder—Mercaptopurine—ulcerative colitis	0.000246	0.00532	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—PRTN3—ulcerative colitis	0.000245	0.0303	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—PTGS1—ulcerative colitis	0.000243	0.03	CbGpPWpGaD
Nepafenac—Immune system disorder—Nicotine—ulcerative colitis	0.000238	0.00516	CcSEcCtD
Nepafenac—Eye pain—Mesalazine—ulcerative colitis	0.000237	0.00512	CcSEcCtD
Nepafenac—Cataract—Hydrocortisone—ulcerative colitis	0.00022	0.00476	CcSEcCtD
Nepafenac—Arthritis—Mesalazine—ulcerative colitis	0.00022	0.00476	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ulcerative colitis	0.000216	0.0266	CbGpPWpGaD
Nepafenac—PTGS2—Fluocinonide—Methylprednisolone—ulcerative colitis	0.000215	0.119	CbGdCrCtD
Nepafenac—PTGS2—Fluocinonide—Dexamethasone—ulcerative colitis	0.000211	0.118	CbGdCrCtD
Nepafenac—PTGS2—Fluocinonide—Betamethasone—ulcerative colitis	0.000211	0.118	CbGdCrCtD
Nepafenac—Dermatitis atopic—Prednisone—ulcerative colitis	0.00021	0.00455	CcSEcCtD
Nepafenac—Cataract—Triamcinolone—ulcerative colitis	0.000207	0.00448	CcSEcCtD
Nepafenac—PTGS2—Fluocinonide—Triamcinolone—ulcerative colitis	0.000206	0.115	CbGdCrCtD
Nepafenac—PTGS2—Eicosanoid Synthesis—PTGS1—ulcerative colitis	0.000201	0.0249	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—ulcerative colitis	0.0002	0.00434	CcSEcCtD
Nepafenac—Hypertension—Nicotine—ulcerative colitis	0.000198	0.00429	CcSEcCtD
Nepafenac—Dry eye—Hydrocortisone—ulcerative colitis	0.000193	0.00418	CcSEcCtD
Nepafenac—Dry mouth—Nicotine—ulcerative colitis	0.000191	0.00414	CcSEcCtD
Nepafenac—Sinusitis—Budesonide—ulcerative colitis	0.00019	0.00411	CcSEcCtD
Nepafenac—Skin disorder—Mercaptopurine—ulcerative colitis	0.000188	0.00407	CcSEcCtD
Nepafenac—Cataract—Betamethasone—ulcerative colitis	0.000188	0.00406	CcSEcCtD
Nepafenac—Cataract—Dexamethasone—ulcerative colitis	0.000188	0.00406	CcSEcCtD
Nepafenac—Nervous system disorder—Nicotine—ulcerative colitis	0.000184	0.00398	CcSEcCtD
Nepafenac—Diabetes mellitus—Prednisolone—ulcerative colitis	0.000179	0.00387	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—CRP—ulcerative colitis	0.000175	0.0216	CbGpPWpGaD
Nepafenac—Diabetes mellitus—Hydrocortisone—ulcerative colitis	0.000175	0.00378	CcSEcCtD
Nepafenac—Ketorolac—PTGS1—ulcerative colitis	0.000172	0.0532	CrCbGaD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—ulcerative colitis	0.000171	0.0211	CbGpPWpGaD
Nepafenac—Eye disorder—Budesonide—ulcerative colitis	0.00017	0.00367	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—PTGS1—ulcerative colitis	0.000169	0.0208	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Mercaptopurine—ulcerative colitis	0.000167	0.00361	CcSEcCtD
Nepafenac—Dry eye—Dexamethasone—ulcerative colitis	0.000165	0.00357	CcSEcCtD
Nepafenac—Dry eye—Betamethasone—ulcerative colitis	0.000165	0.00357	CcSEcCtD
Nepafenac—Angiopathy—Budesonide—ulcerative colitis	0.000165	0.00357	CcSEcCtD
Nepafenac—Bromfenac—PTGS1—ulcerative colitis	0.000165	0.051	CrCbGaD
Nepafenac—Diabetes mellitus—Triamcinolone—ulcerative colitis	0.000164	0.00356	CcSEcCtD
Nepafenac—Immune system disorder—Budesonide—ulcerative colitis	0.000164	0.00355	CcSEcCtD
Nepafenac—Diabetes mellitus—Methylprednisolone—ulcerative colitis	0.000164	0.00355	CcSEcCtD
Nepafenac—Cataract—Prednisone—ulcerative colitis	0.000163	0.00354	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Nicotine—ulcerative colitis	0.000162	0.0035	CcSEcCtD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—ulcerative colitis	0.000161	0.0199	CbGpPWpGaD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—CALM3—ulcerative colitis	0.000156	0.0193	CbGpPWpGaD
Nepafenac—Sinusitis—Mesalazine—ulcerative colitis	0.000154	0.00334	CcSEcCtD
Nepafenac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—ulcerative colitis	0.00015	0.0185	CbGpPWpGaD
Nepafenac—Diabetes mellitus—Betamethasone—ulcerative colitis	0.000149	0.00323	CcSEcCtD
Nepafenac—Diabetes mellitus—Dexamethasone—ulcerative colitis	0.000149	0.00323	CcSEcCtD
Nepafenac—Vision blurred—Budesonide—ulcerative colitis	0.000149	0.00323	CcSEcCtD
Nepafenac—Immune system disorder—Azathioprine—ulcerative colitis	0.000146	0.00317	CcSEcCtD
Nepafenac—Eye pain—Dexamethasone—ulcerative colitis	0.000144	0.00311	CcSEcCtD
Nepafenac—Eye pain—Betamethasone—ulcerative colitis	0.000144	0.00311	CcSEcCtD
Nepafenac—Hypersensitivity—Mercaptopurine—ulcerative colitis	0.000142	0.00308	CcSEcCtD
Nepafenac—Tiaprofenic acid—PTGS1—ulcerative colitis	0.00014	0.0434	CrCbGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—CRP—ulcerative colitis	0.000139	0.0172	CbGpPWpGaD
Nepafenac—Hypersensitivity—Nicotine—ulcerative colitis	0.000138	0.00299	CcSEcCtD
Nepafenac—Eye disorder—Mesalazine—ulcerative colitis	0.000138	0.00299	CcSEcCtD
Nepafenac—Hypertension—Budesonide—ulcerative colitis	0.000137	0.00295	CcSEcCtD
Nepafenac—Angiopathy—Mesalazine—ulcerative colitis	0.000134	0.0029	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Budesonide—ulcerative colitis	0.000134	0.00289	CcSEcCtD
Nepafenac—Immune system disorder—Mesalazine—ulcerative colitis	0.000133	0.00289	CcSEcCtD
Nepafenac—Pruritus—Nicotine—ulcerative colitis	0.000133	0.00287	CcSEcCtD
Nepafenac—Dry mouth—Budesonide—ulcerative colitis	0.000132	0.00285	CcSEcCtD
Nepafenac—Magnesium salicylate—PTGS1—ulcerative colitis	0.00013	0.0403	CrCbGaD
Nepafenac—Diabetes mellitus—Prednisone—ulcerative colitis	0.00013	0.00281	CcSEcCtD
Nepafenac—PTGS2—Fluticasone Propionate—Methylprednisolone—ulcerative colitis	0.000129	0.0721	CbGdCrCtD
Nepafenac—PTGS2—Fluticasone Propionate—Dexamethasone—ulcerative colitis	0.000127	0.0709	CbGdCrCtD
Nepafenac—PTGS2—Fluticasone Propionate—Betamethasone—ulcerative colitis	0.000127	0.0709	CbGdCrCtD
Nepafenac—Fenbufen—PTGS1—ulcerative colitis	0.000127	0.0395	CrCbGaD
Nepafenac—Nervous system disorder—Budesonide—ulcerative colitis	0.000127	0.00274	CcSEcCtD
Nepafenac—Skin disorder—Budesonide—ulcerative colitis	0.000125	0.00271	CcSEcCtD
Nepafenac—PTGS2—Fluticasone Propionate—Triamcinolone—ulcerative colitis	0.000125	0.0693	CbGdCrCtD
Nepafenac—Dizziness—Nicotine—ulcerative colitis	0.000124	0.00268	CcSEcCtD
Nepafenac—Vomiting—Mercaptopurine—ulcerative colitis	0.000123	0.00266	CcSEcCtD
Nepafenac—Vision blurred—Mesalazine—ulcerative colitis	0.000121	0.00262	CcSEcCtD
Nepafenac—Diclofenac—CXCL8—ulcerative colitis	0.000119	0.037	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—ulcerative colitis	0.000119	0.00258	CcSEcCtD
Nepafenac—Vomiting—Nicotine—ulcerative colitis	0.000119	0.00258	CcSEcCtD
Nepafenac—Headache—Nicotine—ulcerative colitis	0.000117	0.00254	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—PTGS2—ulcerative colitis	0.000117	0.0145	CbGpPWpGaD
Nepafenac—Nausea—Mercaptopurine—ulcerative colitis	0.000115	0.00249	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—CXCL8—ulcerative colitis	0.000114	0.0141	CbGpPWpGaD
Nepafenac—PTGS2—Arachidonic acid metabolism—PTGS1—ulcerative colitis	0.000112	0.0138	CbGpPWpGaD
Nepafenac—Skin disorder—Azathioprine—ulcerative colitis	0.000112	0.00242	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Budesonide—ulcerative colitis	0.000111	0.00241	CcSEcCtD
Nepafenac—Nausea—Nicotine—ulcerative colitis	0.000111	0.00241	CcSEcCtD
Nepafenac—Hypertension—Mesalazine—ulcerative colitis	0.000111	0.0024	CcSEcCtD
Nepafenac—Salsalate—PTGS1—ulcerative colitis	0.000111	0.0343	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—ulcerative colitis	0.000109	0.00235	CcSEcCtD
Nepafenac—Dry mouth—Mesalazine—ulcerative colitis	0.000107	0.00232	CcSEcCtD
Nepafenac—Ketoprofen—CXCL8—ulcerative colitis	0.000106	0.0328	CrCbGaD
Nepafenac—Nervous system disorder—Mesalazine—ulcerative colitis	0.000103	0.00223	CcSEcCtD
Nepafenac—Skin disorder—Mesalazine—ulcerative colitis	0.000102	0.00221	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CALM3—ulcerative colitis	0.000101	0.0125	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Azathioprine—ulcerative colitis	9.95e-05	0.00215	CcSEcCtD
Nepafenac—Ketorolac—PTGS2—ulcerative colitis	9.82e-05	0.0304	CrCbGaD
Nepafenac—Eye disorder—Hydrocortisone—ulcerative colitis	9.82e-05	0.00212	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—ulcerative colitis	9.79e-05	0.0121	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—MPO—ulcerative colitis	9.75e-05	0.0121	CbGpPWpGaD
Nepafenac—PTGS1—Eicosanoid Synthesis—PTGS2—ulcerative colitis	9.72e-05	0.012	CbGpPWpGaD
Nepafenac—Hypersensitivity—Budesonide—ulcerative colitis	9.51e-05	0.00206	CcSEcCtD
Nepafenac—Immune system disorder—Hydrocortisone—ulcerative colitis	9.49e-05	0.00205	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—MIF—ulcerative colitis	9.44e-05	0.0117	CbGpPWpGaD
Nepafenac—Bromfenac—PTGS2—ulcerative colitis	9.41e-05	0.0292	CrCbGaD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—ulcerative colitis	9.27e-05	0.0115	CbGpPWpGaD
Nepafenac—Eye disorder—Methylprednisolone—ulcerative colitis	9.22e-05	0.002	CcSEcCtD
Nepafenac—Fenoprofen—PTGS1—ulcerative colitis	9.15e-05	0.0283	CrCbGaD
Nepafenac—Pruritus—Budesonide—ulcerative colitis	9.13e-05	0.00198	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Mesalazine—ulcerative colitis	9.06e-05	0.00196	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—CXCL8—ulcerative colitis	9.02e-05	0.0112	CbGpPWpGaD
Nepafenac—Angiopathy—Methylprednisolone—ulcerative colitis	8.95e-05	0.00194	CcSEcCtD
Nepafenac—Immune system disorder—Methylprednisolone—ulcerative colitis	8.91e-05	0.00193	CcSEcCtD
Nepafenac—Vision blurred—Prednisolone—ulcerative colitis	8.82e-05	0.00191	CcSEcCtD
Nepafenac—Dizziness—Budesonide—ulcerative colitis	8.53e-05	0.00185	CcSEcCtD
Nepafenac—Hypersensitivity—Azathioprine—ulcerative colitis	8.49e-05	0.00184	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS1—ulcerative colitis	8.48e-05	0.0263	CrCbGaD
Nepafenac—Eye disorder—Dexamethasone—ulcerative colitis	8.39e-05	0.00182	CcSEcCtD
Nepafenac—Eye disorder—Betamethasone—ulcerative colitis	8.39e-05	0.00182	CcSEcCtD
Nepafenac—Vomiting—Budesonide—ulcerative colitis	8.2e-05	0.00178	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MST1—ulcerative colitis	8.19e-05	0.0101	CbGpPWpGaD
Nepafenac—Angiopathy—Dexamethasone—ulcerative colitis	8.14e-05	0.00176	CcSEcCtD
Nepafenac—Angiopathy—Betamethasone—ulcerative colitis	8.14e-05	0.00176	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—ulcerative colitis	8.13e-05	0.0101	CbGpPWpGaD
Nepafenac—Headache—Budesonide—ulcerative colitis	8.08e-05	0.00175	CcSEcCtD
Nepafenac—Hypertension—Prednisolone—ulcerative colitis	8.08e-05	0.00175	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—MPO—ulcerative colitis	8.03e-05	0.00993	CbGpPWpGaD
Nepafenac—Tiaprofenic acid—PTGS2—ulcerative colitis	8e-05	0.0248	CrCbGaD
Nepafenac—PTGS1—Overview of nanoparticle effects—TNF—ulcerative colitis	7.91e-05	0.00978	CbGpPWpGaD
Nepafenac—Hypertension—Hydrocortisone—ulcerative colitis	7.89e-05	0.00171	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—MPO—ulcerative colitis	7.74e-05	0.00957	CbGpPWpGaD
Nepafenac—Hypersensitivity—Mesalazine—ulcerative colitis	7.73e-05	0.00167	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—ulcerative colitis	7.73e-05	0.00167	CcSEcCtD
Nepafenac—Nausea—Budesonide—ulcerative colitis	7.66e-05	0.00166	CcSEcCtD
Nepafenac—Dizziness—Azathioprine—ulcerative colitis	7.62e-05	0.00165	CcSEcCtD
Nepafenac—Magnesium salicylate—PTGS2—ulcerative colitis	7.44e-05	0.023	CrCbGaD
Nepafenac—Hypertension—Triamcinolone—ulcerative colitis	7.43e-05	0.00161	CcSEcCtD
Nepafenac—Pruritus—Mesalazine—ulcerative colitis	7.42e-05	0.00161	CcSEcCtD
Nepafenac—Hypertension—Methylprednisolone—ulcerative colitis	7.42e-05	0.00161	CcSEcCtD
Nepafenac—Vomiting—Azathioprine—ulcerative colitis	7.33e-05	0.00159	CcSEcCtD
Nepafenac—Nervous system disorder—Hydrocortisone—ulcerative colitis	7.32e-05	0.00158	CcSEcCtD
Nepafenac—Eye disorder—Prednisone—ulcerative colitis	7.3e-05	0.00158	CcSEcCtD
Nepafenac—Fenbufen—PTGS2—ulcerative colitis	7.28e-05	0.0226	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ulcerative colitis	7.26e-05	0.00157	CcSEcCtD
Nepafenac—Skin disorder—Hydrocortisone—ulcerative colitis	7.25e-05	0.00157	CcSEcCtD
Nepafenac—Headache—Azathioprine—ulcerative colitis	7.22e-05	0.00156	CcSEcCtD
Nepafenac—Dry mouth—Triamcinolone—ulcerative colitis	7.17e-05	0.00155	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—PTGS1—ulcerative colitis	7.12e-05	0.00881	CbGpPWpGaD
Nepafenac—Angiopathy—Prednisone—ulcerative colitis	7.09e-05	0.00153	CcSEcCtD
Nepafenac—Immune system disorder—Prednisone—ulcerative colitis	7.06e-05	0.00153	CcSEcCtD
Nepafenac—Dizziness—Mesalazine—ulcerative colitis	6.94e-05	0.0015	CcSEcCtD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—ulcerative colitis	6.92e-05	0.00855	CbGpPWpGaD
Nepafenac—Nervous system disorder—Methylprednisolone—ulcerative colitis	6.88e-05	0.00149	CcSEcCtD
Nepafenac—Nausea—Azathioprine—ulcerative colitis	6.84e-05	0.00148	CcSEcCtD
Nepafenac—Skin disorder—Methylprednisolone—ulcerative colitis	6.81e-05	0.00147	CcSEcCtD
Nepafenac—Hypertension—Betamethasone—ulcerative colitis	6.74e-05	0.00146	CcSEcCtD
Nepafenac—Hypertension—Dexamethasone—ulcerative colitis	6.74e-05	0.00146	CcSEcCtD
Nepafenac—Vomiting—Mesalazine—ulcerative colitis	6.67e-05	0.00144	CcSEcCtD
Nepafenac—Magnesium salicylate—ALB—ulcerative colitis	6.63e-05	0.0205	CrCbGaD
Nepafenac—Headache—Mesalazine—ulcerative colitis	6.57e-05	0.00142	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Hydrocortisone—ulcerative colitis	6.44e-05	0.00139	CcSEcCtD
Nepafenac—Vision blurred—Prednisone—ulcerative colitis	6.41e-05	0.00139	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—IL6—ulcerative colitis	6.39e-05	0.00789	CbGpPWpGaD
Nepafenac—Salsalate—PTGS2—ulcerative colitis	6.33e-05	0.0196	CrCbGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—TNF—ulcerative colitis	6.28e-05	0.00776	CbGpPWpGaD
Nepafenac—Nervous system disorder—Betamethasone—ulcerative colitis	6.25e-05	0.00135	CcSEcCtD
Nepafenac—Nervous system disorder—Dexamethasone—ulcerative colitis	6.25e-05	0.00135	CcSEcCtD
Nepafenac—Nausea—Mesalazine—ulcerative colitis	6.23e-05	0.00135	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—FCGR2A—ulcerative colitis	6.2e-05	0.00766	CbGpPWpGaD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—ulcerative colitis	6.15e-05	0.0076	CbGpPWpGaD
Nepafenac—Diclofenac—PTGS1—ulcerative colitis	6.1e-05	0.0189	CrCbGaD
Nepafenac—Mebendazole—ABCB1—ulcerative colitis	6.07e-05	0.0188	CrCbGaD
Nepafenac—Hypertension—Prednisone—ulcerative colitis	5.87e-05	0.00127	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ulcerative colitis	5.75e-05	0.00125	CcSEcCtD
Nepafenac—Hypersensitivity—Prednisolone—ulcerative colitis	5.63e-05	0.00122	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Betamethasone—ulcerative colitis	5.5e-05	0.00119	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Dexamethasone—ulcerative colitis	5.5e-05	0.00119	CcSEcCtD
Nepafenac—Hypersensitivity—Hydrocortisone—ulcerative colitis	5.5e-05	0.00119	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—ulcerative colitis	5.45e-05	0.00674	CbGpPWpGaD
Nepafenac—Nervous system disorder—Prednisone—ulcerative colitis	5.44e-05	0.00118	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—PTGS2—ulcerative colitis	5.41e-05	0.00668	CbGpPWpGaD
Nepafenac—Ketoprofen—PTGS1—ulcerative colitis	5.4e-05	0.0167	CrCbGaD
Nepafenac—Skin disorder—Prednisone—ulcerative colitis	5.39e-05	0.00117	CcSEcCtD
Nepafenac—Pruritus—Hydrocortisone—ulcerative colitis	5.28e-05	0.00114	CcSEcCtD
Nepafenac—Fenoprofen—PTGS2—ulcerative colitis	5.23e-05	0.0162	CrCbGaD
Nepafenac—Hypersensitivity—Triamcinolone—ulcerative colitis	5.18e-05	0.00112	CcSEcCtD
Nepafenac—Hypersensitivity—Methylprednisolone—ulcerative colitis	5.17e-05	0.00112	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—CRP—ulcerative colitis	5.13e-05	0.00634	CbGpPWpGaD
Nepafenac—PTGS2—Overview of nanoparticle effects—IL6—ulcerative colitis	5.07e-05	0.00627	CbGpPWpGaD
Nepafenac—Dizziness—Prednisolone—ulcerative colitis	5.05e-05	0.00109	CcSEcCtD
Nepafenac—Pruritus—Triamcinolone—ulcerative colitis	4.97e-05	0.00108	CcSEcCtD
Nepafenac—Pruritus—Methylprednisolone—ulcerative colitis	4.96e-05	0.00107	CcSEcCtD
Nepafenac—Dizziness—Hydrocortisone—ulcerative colitis	4.93e-05	0.00107	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS2—ulcerative colitis	4.85e-05	0.015	CrCbGaD
Nepafenac—Headache—Prednisolone—ulcerative colitis	4.79e-05	0.00104	CcSEcCtD
Nepafenac—Vomiting—Hydrocortisone—ulcerative colitis	4.74e-05	0.00103	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—RELA—ulcerative colitis	4.72e-05	0.00583	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—ICAM1—ulcerative colitis	4.71e-05	0.00583	CbGpPWpGaD
Nepafenac—Headache—Hydrocortisone—ulcerative colitis	4.67e-05	0.00101	CcSEcCtD
Nepafenac—Fenoprofen—ALB—ulcerative colitis	4.66e-05	0.0144	CrCbGaD
Nepafenac—Dizziness—Triamcinolone—ulcerative colitis	4.65e-05	0.00101	CcSEcCtD
Nepafenac—Dizziness—Methylprednisolone—ulcerative colitis	4.64e-05	0.001	CcSEcCtD
Nepafenac—Nausea—Prednisolone—ulcerative colitis	4.54e-05	0.000982	CcSEcCtD
Nepafenac—Pruritus—Betamethasone—ulcerative colitis	4.51e-05	0.000976	CcSEcCtD
Nepafenac—Pruritus—Dexamethasone—ulcerative colitis	4.51e-05	0.000976	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—ulcerative colitis	4.48e-05	0.00553	CbGpPWpGaD
Nepafenac—Vomiting—Triamcinolone—ulcerative colitis	4.47e-05	0.000967	CcSEcCtD
Nepafenac—Vomiting—Methylprednisolone—ulcerative colitis	4.46e-05	0.000965	CcSEcCtD
Nepafenac—Nausea—Hydrocortisone—ulcerative colitis	4.43e-05	0.000959	CcSEcCtD
Nepafenac—Headache—Triamcinolone—ulcerative colitis	4.4e-05	0.000953	CcSEcCtD
Nepafenac—Headache—Methylprednisolone—ulcerative colitis	4.39e-05	0.000951	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—ulcerative colitis	4.3e-05	0.00531	CbGpPWpGaD
Nepafenac—Dizziness—Betamethasone—ulcerative colitis	4.22e-05	0.000913	CcSEcCtD
Nepafenac—Dizziness—Dexamethasone—ulcerative colitis	4.22e-05	0.000913	CcSEcCtD
Nepafenac—Nausea—Triamcinolone—ulcerative colitis	4.17e-05	0.000903	CcSEcCtD
Nepafenac—Nausea—Methylprednisolone—ulcerative colitis	4.16e-05	0.000901	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ulcerative colitis	4.16e-05	0.00514	CbGpPWpGaD
Nepafenac—Hypersensitivity—Prednisone—ulcerative colitis	4.09e-05	0.000885	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—CRP—ulcerative colitis	4.07e-05	0.00503	CbGpPWpGaD
Nepafenac—Vomiting—Dexamethasone—ulcerative colitis	4.05e-05	0.000877	CcSEcCtD
Nepafenac—Vomiting—Betamethasone—ulcerative colitis	4.05e-05	0.000877	CcSEcCtD
Nepafenac—Headache—Betamethasone—ulcerative colitis	3.99e-05	0.000865	CcSEcCtD
Nepafenac—Headache—Dexamethasone—ulcerative colitis	3.99e-05	0.000865	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—ulcerative colitis	3.98e-05	0.00492	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ulcerative colitis	3.98e-05	0.00492	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—ALB—ulcerative colitis	3.93e-05	0.00486	CbGpPWpGaD
Nepafenac—Pruritus—Prednisone—ulcerative colitis	3.93e-05	0.00085	CcSEcCtD
Nepafenac—Oxcarbazepine—ALB—ulcerative colitis	3.91e-05	0.0121	CrCbGaD
Nepafenac—Nausea—Dexamethasone—ulcerative colitis	3.79e-05	0.00082	CcSEcCtD
Nepafenac—Nausea—Betamethasone—ulcerative colitis	3.79e-05	0.00082	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—ICAM1—ulcerative colitis	3.74e-05	0.00463	CbGpPWpGaD
Nepafenac—Dizziness—Prednisone—ulcerative colitis	3.67e-05	0.000795	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—IFNG—ulcerative colitis	3.59e-05	0.00443	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—RELA—ulcerative colitis	3.54e-05	0.00437	CbGpPWpGaD
Nepafenac—Vomiting—Prednisone—ulcerative colitis	3.53e-05	0.000764	CcSEcCtD
Nepafenac—Diclofenac—PTGS2—ulcerative colitis	3.48e-05	0.0108	CrCbGaD
Nepafenac—Headache—Prednisone—ulcerative colitis	3.48e-05	0.000753	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—PTGS2—ulcerative colitis	3.44e-05	0.00425	CbGpPWpGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ulcerative colitis	3.4e-05	0.0042	CbGpPWpGaD
Nepafenac—Nausea—Prednisone—ulcerative colitis	3.3e-05	0.000714	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—IL1B—ulcerative colitis	3.2e-05	0.00395	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—ALB—ulcerative colitis	3.12e-05	0.00386	CbGpPWpGaD
Nepafenac—Diclofenac—ALB—ulcerative colitis	3.1e-05	0.00961	CrCbGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—TNF—ulcerative colitis	3.1e-05	0.00383	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TLR4—ulcerative colitis	3.09e-05	0.00382	CbGpPWpGaD
Nepafenac—Ketoprofen—PTGS2—ulcerative colitis	3.09e-05	0.00956	CrCbGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—NFKB1—ulcerative colitis	2.98e-05	0.00369	CbGpPWpGaD
Nepafenac—Diclofenac—ABCB1—ulcerative colitis	2.96e-05	0.00917	CrCbGaD
Nepafenac—PTGS2—Spinal Cord Injury—ICAM1—ulcerative colitis	2.96e-05	0.00366	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ulcerative colitis	2.9e-05	0.00358	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—CD4—ulcerative colitis	2.85e-05	0.00353	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IFNG—ulcerative colitis	2.85e-05	0.00352	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—RELA—ulcerative colitis	2.81e-05	0.00347	CbGpPWpGaD
Nepafenac—Ketoprofen—ALB—ulcerative colitis	2.75e-05	0.00852	CrCbGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ulcerative colitis	2.68e-05	0.00332	CbGpPWpGaD
Nepafenac—Carbamazepine—ABCB1—ulcerative colitis	2.54e-05	0.00787	CrCbGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IL1B—ulcerative colitis	2.54e-05	0.00314	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—NFKB1—ulcerative colitis	2.37e-05	0.00293	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—TNF—ulcerative colitis	2.32e-05	0.00287	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IFNG—ulcerative colitis	2.25e-05	0.00278	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CHP1—ulcerative colitis	2.15e-05	0.00266	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CXCL8—ulcerative colitis	2.09e-05	0.00259	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CHP1—ulcerative colitis	2.04e-05	0.00252	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL1B—ulcerative colitis	2.01e-05	0.00248	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL2—ulcerative colitis	2e-05	0.00247	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MMP9—ulcerative colitis	1.89e-05	0.00234	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—IL6—ulcerative colitis	1.87e-05	0.00232	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—DLD—ulcerative colitis	1.86e-05	0.0023	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—TNF—ulcerative colitis	1.84e-05	0.00228	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CHP1—ulcerative colitis	1.71e-05	0.00211	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SEL1L—ulcerative colitis	1.62e-05	0.002	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—ulcerative colitis	1.6e-05	0.00198	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TGFB1—ulcerative colitis	1.56e-05	0.00193	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—IL6—ulcerative colitis	1.49e-05	0.00184	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—DLD—ulcerative colitis	1.47e-05	0.00182	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TNF—ulcerative colitis	1.46e-05	0.0018	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LTF—ulcerative colitis	1.45e-05	0.0018	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TP53—ulcerative colitis	1.28e-05	0.00159	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—ulcerative colitis	1.27e-05	0.00158	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL6—ulcerative colitis	1.18e-05	0.00145	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—ulcerative colitis	1.06e-05	0.00131	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SLC11A1—ulcerative colitis	1.04e-05	0.00128	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—ulcerative colitis	9.91e-06	0.00123	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—ulcerative colitis	9.82e-06	0.00121	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MAML2—ulcerative colitis	9.3e-06	0.00115	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—ALB—ulcerative colitis	8.83e-06	0.00109	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ulcerative colitis	8.74e-06	0.00108	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CALM3—ulcerative colitis	8.08e-06	0.000999	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—ulcerative colitis	7.8e-06	0.000964	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—ulcerative colitis	7.73e-06	0.000955	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CALM3—ulcerative colitis	7.66e-06	0.000947	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PTGS1—ulcerative colitis	7.13e-06	0.000881	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—ALB—ulcerative colitis	7.01e-06	0.000866	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CALM3—ulcerative colitis	6.42e-06	0.000793	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ABCB1—ulcerative colitis	6.29e-06	0.000777	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ADCY5—ulcerative colitis	5.86e-06	0.000725	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ADCY5—ulcerative colitis	5.56e-06	0.000687	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ABCB1—ulcerative colitis	4.99e-06	0.000617	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ADCY5—ulcerative colitis	4.66e-06	0.000575	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PPARG—ulcerative colitis	4.37e-06	0.000541	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ALB—ulcerative colitis	3.93e-06	0.000486	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PPARG—ulcerative colitis	3.47e-06	0.000429	CbGpPWpGaD
Nepafenac—PTGS2—Disease—JAK2—ulcerative colitis	3.47e-06	0.000428	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTGS2—ulcerative colitis	3.44e-06	0.000425	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CD4—ulcerative colitis	3.29e-06	0.000406	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ALB—ulcerative colitis	3.12e-06	0.000386	CbGpPWpGaD
Nepafenac—PTGS2—Disease—STAT3—ulcerative colitis	2.54e-06	0.000314	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TGFB1—ulcerative colitis	2.36e-06	0.000291	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IL6—ulcerative colitis	1.78e-06	0.00022	CbGpPWpGaD
